Skye Bioscience, Inc. (SKYE)

Market Cap	71.57M
Revenue (ttm)	n/a
Net Income (ttm)	-32.65M
Shares Out	30.98M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	426,076
Open	2.390
Previous Close	2.240
Day's Range	2.250 - 2.450
52-Week Range	1.140 - 12.105
Beta	1.75
Analysts	Buy
Price Target	16.60 (+618.62%)
Earnings Date	May 8, 2025

About SKYE

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Die...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: SKYE
• Website: https://skyebioscience.com

Analyst Forecast

According to 6 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price forecast is $16.6, which is an increase of 618.62% from the latest price.

Price Target

$16.6

(618.62% upside)

Analyst Consensus: Buy